Comparison of a New In-House and Three Published HLA-B*15:02 Screening Methods for Prevention of Carbamazepine-Induced Severe Drug Reactions

Jaruthamsophon, Kanoot; Sripo, Thanya; Sukasem, Chonlaphat; Limprasert, Pornprot

doi:10.1371/journal.pone.0155907

Cited by 8 publications

(14 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…His symptoms were aggravated when he moved quickly. He was diagnosed with paroxysmal kinesigenic dyskinesia and was screened for HLA-B*15:02 by a validated in-house method9. HLA-B*15:02 screening was negative and the patient was prescribed CBZ 200 mg per day.…”

Section: Resultsmentioning

confidence: 99%

HLA-B*15:21 and carbamazepine-induced Stevens-Johnson syndrome: pooled-data and in silico analysis

Jaruthamsophon

Tipmanee

Sangiemchoey

et al. 2017

Sci Rep

Self Cite

View full text Add to dashboard Cite

HLA-B*15:02 screening before carbamazepine (CBZ) prescription in Asian populations is the recommended practice to prevent CBZ-induced Stevens-Johnson syndrome (CBZ-SJS). However, a number of patients have developed CBZ-SJS even having no HLA-B*15:02. Herein, we present the case of a Thai patient who had a negative HLA-B*15:02 screening result but later developed CBZ-SJS. Further HLA typing revealed HLA-B*15:21/B*13:01. HLA-B*15:21 is a member of the HLA-B75 serotype and is commonly found in Southeast Asian populations. Based on this case, we hypothesised that if all HLA-B*15:02 carriers were prevented from CBZ prescription, another common HLA-B75 serotype marker would show its association with CBZ-SJS. To test this hypothesis, we pooled data from previous association studies in Asian populations, excluded all cases with HLA-B*15:02, and analysed the association significance of HLA-B75 serotype markers. A significant association was found between CBZ-SJS and HLA-B*15:21 and HLA-B*15:11. We also applied an in silico analysis and found that all HLA-B75 serotype molecules shared similar capability in binding the CBZ molecule. In summary, this report provides the first evidence of a positive association between HLA-B*15:21 and CBZ-SJS and the first in silico analysis of CBZ binding sites and details of the molecular behaviour of HLA-B75 molecule to explain its molecular action.

show abstract

Section: Resultsmentioning

confidence: 99%

HLA-B*15:21 and carbamazepine-induced Stevens-Johnson syndrome: pooled-data and in silico analysis

Jaruthamsophon

Tipmanee

Sangiemchoey

et al. 2017

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…This assay requires just less than 1 hour per allele, therefore the total time for detection of both alleles is the same as that of our assay. However, the drawback of LAMP is that cross‐contamination can occur from the first to the second PCR because of its high sensitivity and the high concentration of PCR products used in the assay …”

Section: Discussionmentioning

confidence: 99%

“…However, the recent assays proposed for the screening test are only able to detect the HLA‐B*15:02 allele or the HLA‐A*31:01 allele, separately. Consequently, this can raise the cost and time requirement for performing the screening test.…”

Section: Introductionmentioning

confidence: 99%

A novel multiplex polymerase chain reaction assay for detection of both HLA‐A31:01/HLA‐B15:02 alleles, which confer susceptibility to carbamazepine‐induced severe cutaneous adverse reactions

Nguyen

Vidal

et al. 2017

HLA

View full text Add to dashboard Cite

HLA-A*31:01 and HLA-B*15:02 have been widely reported to confer genetic susceptibility to carbamazepine (CBZ)-induced severe cutaneous adverse reactions (SCARs). Accordingly, the screening for these alleles has been highly recommended to prevent SCAR prior to introducing CBZ therapy. Although a number of methods are available for screening of HLA-A*31:01 or HLA-B*15:02 alleles separately, developing an assay that can detect both these alleles would be more clinically practical, cost-effective and less time-consuming. Therefore, in this study, a multiplex polymerase chain reaction (PCR) using TaqMan Probe was designed and validated to be able to detect HLA-A*31:01 and HLA-B*15:02. In comparison with Luminex-SSO/SBT/SSB, the multiplex PCR assay for detection of HLA-A*31:01 and HLA-B*15:02 had a perfect agreement in the validation group of 125 samples. The method was able to detect the target genes at the DNA concentration of 0.037 ng/μL. The unit cost of this assay is less than $5 USD with total time of 110 minutes.

show abstract

“… 12 , 13 Furthermore, HLA-B*15:02 screening methods should also be considered for the prevention of carbamazepine-induced severe drug reactions. 14 …”

Section: Current Management Strategies Of Focal Seizuresmentioning

confidence: 99%

“…Before starting treatment with CBZ or OXC, the opportunity to perform a HLA genetic profile to assess the potential risk of vasculitic reactions should be taken into consideration. 14 …”

Section: Current Management Strategies Of Focal Seizuresmentioning

confidence: 99%

New developments in the management of partial-onset epilepsy: role of brivaracetam

Coppola¹,

Iapadre²,

Operto³

et al. 2017

DDDT

View full text Add to dashboard Cite

Currently, a number of novel anticonvulsant drugs, the so-called third generation, are in various stages of development. Several of them are already available or in ongoing clinical trials. These new compounds should take advantage of new insights into the basic pathophysiology of epileptogenesis, drug metabolism and drug interactions. Many of them still need to be further evaluated mainly in real-world observational trials and registries. Among newer anticonvulsant drugs for partial-onset seizures (POSs), rufinamide, lacosamide, eslicarbazepine and perampanel are those new treatment options for which more substantial clinical evidence is currently available, both in adults and, to some extent, in children. Among the newest anticonvulsant drugs, brivaracetam, a high-affinity synaptic vesicle protein 2A ligand, reported to be 10- to 30-fold more potent than levetiracetam, is highly effective in a broad range of experimental models of focal and generalized seizures. Unlike levetiracetam, brivaracetam does not inhibit high-voltage Ca2+ channels and AMPA receptors and appears to inhibit neuronal voltage-gated sodium channels playing a role as a partial antagonist. Brivaracetam has a linear pharmacokinetic profile, is extensively metabolized and is excreted by urine (only 8%–11% unchanged). It does not seem to influence the pharmacokinetics of other antiepileptic drugs. It was approved in the European Union in January 2016 and in the US in February 2016 as an adjunctive therapy for the treatment of POS in patients older than 16 years of age. To date, its clinical efficacy as adjunctive antiepileptic treatment in adults with refractory POS at doses between 50 and 200 mg daily has been extensively assessed in two Phase IIb and four Phase III randomized controlled studies. Long-term extension studies show sustained efficacy of brivaracetam. Overall, the drug is generally well tolerated with only mild-to-moderate side effects. This is true also by intravenous route. Brivaracetam has not yet been evaluated as monotherapy or in comparison with other new anticonvulsant drugs.

show abstract

Comparison of a New In-House and Three Published HLA-B*15:02 Screening Methods for Prevention of Carbamazepine-Induced Severe Drug Reactions

Cited by 8 publications

References 21 publications

HLA-B*15:21 and carbamazepine-induced Stevens-Johnson syndrome: pooled-data and in silico analysis

HLA-B*15:21 and carbamazepine-induced Stevens-Johnson syndrome: pooled-data and in silico analysis

A novel multiplex polymerase chain reaction assay for detection of both HLA‐A31:01/HLA‐B15:02 alleles, which confer susceptibility to carbamazepine‐induced severe cutaneous adverse reactions

New developments in the management of partial-onset epilepsy: role of brivaracetam

Contact Info

Product

Resources

About

Comparison of a New In-House and Three Published HLA-B*15:02 Screening Methods for Prevention of Carbamazepine-Induced Severe Drug Reactions

Cited by 8 publications

References 21 publications

HLA-B*15:21 and carbamazepine-induced Stevens-Johnson syndrome: pooled-data and in silico analysis

HLA-B*15:21 and carbamazepine-induced Stevens-Johnson syndrome: pooled-data and in silico analysis

A novel multiplex polymerase chain reaction assay for detection of both HLA‐A*31:01/HLA‐B*15:02 alleles, which confer susceptibility to carbamazepine‐induced severe cutaneous adverse reactions

New developments in the management of partial-onset epilepsy: role of brivaracetam

Contact Info

Product

Resources

About

A novel multiplex polymerase chain reaction assay for detection of both HLA‐A31:01/HLA‐B15:02 alleles, which confer susceptibility to carbamazepine‐induced severe cutaneous adverse reactions